Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study
PRO-based surveillance showed satisfactory QOL and stable symptom control in PSROC after long-term period of niraparib maintenance, regardless of BRCA status. This real-world research highlights the significance of long-term usage of niraparib and PROs in PSROC management.
Authors
- Danbo Wang (ORCID: https://orcid.org/0000-0002-8925-364X)
- Guonan Zhang (ORCID: https://orcid.org/0000-0002-2228-9197)
- Jundong Li
- Dongyan Cao
- Peng Peng
- Jie Tang
- Yang Xiang
- Yang Sun
- Ming Du
- Yue Wang
- Hui Zhang
- Ninghai Cheng
- Liangqing Yao
- Ge Lou
Institutions
- Hebei Medical University (CN)
- Fujian Medical University (CN)
- Central South University (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Guangzhou Women and Children Medical Center (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hunan Cancer Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Henan Provincial People's Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1186/s13048-026-01980-8
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 24.20